Natasha Leighl

Natasha Leighl is a Canadian lung cancer leader whose research bridges EGFR-targeted therapy innovations with real-world implementation challenges. She has contributed to international guidelines for EGFR testing and treatment and championed global access to ctDNA-based testing in low-resource settings. Her research program includes patient-reported outcomes in EGFR-mutant NSCLC and comparative effectiveness of osimertinib versus earlier-generation agents. She co-leads international collaborative networks in thoracic oncology.